- Home
- MOBX vs ALVR Comparison
MOBX vs ALVR Comparison
Compare MOBX & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOBX
- ALVR
- Stock Information
- Founded
- MOBX 2020
- ALVR 2013
- Country
- MOBX United States
- ALVR United States
- Employees
- MOBX N/A
- ALVR N/A
- Industry
- MOBX
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MOBX
- ALVR Health Care
- Exchange
- MOBX Nasdaq
- ALVR Nasdaq
- Market Cap
- MOBX 46.9M
- ALVR 48.8M
- IPO Year
- MOBX N/A
- ALVR 2020
- Fundamental
- Price
- MOBX $1.26
- ALVR $9.63
- Analyst Decision
- MOBX
- ALVR
- Analyst Count
- MOBX 0
- ALVR 0
- Target Price
- MOBX N/A
- ALVR N/A
- AVG Volume (30 Days)
- MOBX 507.2K
- ALVR 22.4K
- Earning Date
- MOBX 02-18-2025
- ALVR 03-14-2025
- Dividend Yield
- MOBX N/A
- ALVR N/A
- EPS Growth
- MOBX N/A
- ALVR N/A
- EPS
- MOBX N/A
- ALVR N/A
- Revenue
- MOBX $9,326,000.00
- ALVR N/A
- Revenue This Year
- MOBX N/A
- ALVR N/A
- Revenue Next Year
- MOBX N/A
- ALVR N/A
- P/E Ratio
- MOBX N/A
- ALVR N/A
- Revenue Growth
- MOBX 1023.61
- ALVR N/A
- 52 Week Low
- MOBX $0.55
- ALVR $7.96
- 52 Week High
- MOBX $3.62
- ALVR $24.15
- Technical
- Relative Strength Index (RSI)
- MOBX 47.25
- ALVR 45.63
- Support Level
- MOBX $1.24
- ALVR $9.55
- Resistance Level
- MOBX $1.41
- ALVR $10.41
- Average True Range (ATR)
- MOBX 0.12
- ALVR 0.44
- MACD
- MOBX 0.01
- ALVR 0.05
- Stochastic Oscillator
- MOBX 37.14
- ALVR 22.77
About MOBX Mobix Labs Inc.
Mobix Labs Inc. specializes in designing, developing, and selling components and systems for wireless and wired connectivity, radio frequency (RF) technologies, switching, and electromagnetic interference (EMI) filtering solutions. The company serves markets, including commercial, industrial, automotive, medical, aerospace, defense, and others.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.